



# Pathophysiological and platelet anti-aggregatory effects of nitric oxide

Andrew Sean Holmes, BSc (Hons)

A thesis submitted to The University of Adelaide as the  
requirement for the degree of

*Doctor of Philosophy*

The Cardiology Unit,  
North Western Adelaide Health Services,  
Department of Medicine,  
The University of Adelaide

*January 2003*

# Table of Contents

<b>TABLE OF CONTENTS</b> .....	<b>2</b>
<b>INDEX OF FIGURES</b> .....	<b>13</b>
<b>LIST OF TABLES</b> .....	<b>16</b>
<b>THESIS SUMMARY</b> .....	<b>18</b>
BACKGROUND.....	18
STUDIES EXAMINING THE PHENOMENA OF PLATELET HYPER-AGGREGABILITY AND HYPO-RESPONSIVENESS TO DONORS OF NITRIC OXIDE; INVOLVEMENT OF SUPEROXIDE .....	19
<i>Background</i> .....	19
<i>Study #1</i> .....	19
<i>Study #2</i> .....	20
<i>Study #3</i> .....	20
<i>Conclusions</i> .....	21
STUDIES EXAMINING THE DETERMINANTS OF PLATELET HYPO-RESPONSIVENESS TO DONORS OF NITRIC OXIDE .....	22
<i>Background</i> .....	22
<i>Study</i> .....	22
<i>Conclusions</i> .....	23
STUDIES EVALUATING THE ANTI-AGGREGATORY AND ARTERIAL VASOMOTOR EFFECTS OF PROPHYLACTIC NITRATE PHARMACOTHERAPY .....	23
<i>Background</i> .....	23
<i>Study</i> .....	23
<i>Conclusions</i> .....	24
<b>DECLARATION</b> .....	<b>25</b>
<b>ACKNOWLEDGEMENTS</b> .....	<b>26</b>
<b>PUBLICATIONS AND PRESENTATIONS</b> .....	<b>28</b>
<b>CHAPTER 1: INTRODUCTION; PATHOPHYSIOLOGICAL AND PLATELET ANTI-AGGREGATORY EFFECTS OF NITRIC OXIDE</b> .....	<b>30</b>
<b>CHAPTER 1: OVERVIEW</b> .....	<b>31</b>
<b>SECTION A: NORMAL VASCULAR PHYSIOLOGY</b> -.....	<b>33</b>
<b>NITRIC OXIDE</b> .....	<b>33</b>
[A.1] ENDOTHELIAL-DERIVED RELAXING FACTOR AND NITRIC OXIDE .....	33
[A.1.1] <i>Discovery of EDRF</i> .....	33
[A.1.2] <i>Identification of endothelium derived relaxing factor as nitric oxide or a nitric oxide         compound</i> .....	33
[A.1.3] <i>Reactivity</i> .....	34
[A.1.4] <i>Nitroxyl/nitrosonium</i> .....	34
[A.1.5] <i>S-nitroso-thiols</i> .....	35
[A.2] BIOCHEMISTRY .....	36
[A.2.1] <i>Synthesis of nitric oxide</i> .....	36
[A.2.2] <i>Nitric Oxide Synthase</i> .....	36
[A.2.2.1] <i>Co-factors</i> .....	37
[A.3] VASCULAR AND PERIVASCULAR DISTRIBUTION OF NITRIC OXIDE, NITRIC OXIDE CONGENERS AND AGENTS AFFECTING NITRIC OXIDE'S ACTION .....	39
[A.3.1] <i>Nitric Oxide Synthase</i> .....	39
[A.3.1.1] <i>Endothelial nitric oxide synthase (eNOS)</i> .....	39
[A.3.1.1.1] <i>Platelet eNOS</i> .....	39

[A.3.1.1.2] eNOS Regulation .....	39
[A.3.1.2] Inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS).....	40
[A.3.2] <i>Superoxide</i> .....	41
[A.3.2.1] Components of NAD(P)H oxidase .....	41
[A.3.2.2] Distribution and function of non-phagocyte NAD(P)H oxidase.....	42
<b>NORMAL PLATELET FUNCTION: ROLE OF NITRIC OXIDE .....</b>	<b>43</b>
<b>PLATELET PHYSIOLOGY .....</b>	<b>43</b>
[A.4] PLATELET ULTRA-STRUCTURE .....	43
[A.4.1] <i>α-Granules</i> .....	44
[A.4.2] <i>Dense body granules</i> .....	44
[A.5] PLATELET ADHESION .....	45
[A.5.1] <i>GPIb/IX/V receptor complex</i> .....	45
[A.5.2] <i>Von Willebrand factor (vWf)</i> .....	46
[A.5.2.1] vWf and ischaemic heart disease .....	46
[A.6] MECHANISMS OF PLATELET ACTIVATION .....	46
[A.6.1] <i>Strong/Weak Agonists</i> .....	47
[A.6.2] <i>Thrombin Receptor</i> .....	47
[A.6.3] <i>Adenosine di-phosphate receptor</i> .....	48
[A.6.4] <i>Thromboxane A<sub>2</sub> Receptors</i> .....	50
[A.6.4.1] Clinical significance .....	52
[A.6.5] <i>Other Receptors</i> .....	52
[A.7] PLATELET SHAPE CHANGE .....	52
[A.8] BIOCHEMISTRY OF PLATELET ACTIVATION AND AGGREGATION.....	53
[A.8.1] <i>Biochemical Platelet Activation</i> .....	53
[A.9] PLATELET AGGREGATION .....	55
[A.9.1] <i>Glycoprotein IIb/IIIa (GPIIb/IIIa)</i> .....	55
[A.9.2] <i>Recognition Sequences</i> .....	56
[A.9.3] <i>Arg-Gly-Asp (RGD)</i> .....	56
[A.10] MECHANISM OF PLATELET INHIBITION.....	57
[A.10.1] <i>Prostanoids</i> .....	57
[A.10.1.1] Prostacyclin (PGI <sub>2</sub> ).....	57
[A.10.1.2] Cyclic adenosine 3'5'-monophosphate (cAMP).....	58
[A.11] NITRIC OXIDE .....	59
[A.11.1] <i>Mechanism</i> .....	59
[A.11.1.1] cGMP independent effects of nitric oxide .....	62
[A.12] EFFECTS OF S-NITROSOTHIOLS ON PLATELET FUNCTION.....	62
<b>PLATELET/LEUKOCYTE INTERACTIONS .....</b>	<b>63</b>
[A.13] PLATELET/LEUKOCYTE ATTACHMENT AND SIGNIFICANCE.....	63
<b>PLATELET/ENDOTHELIUM INTERACTIONS.....</b>	<b>64</b>
[A.14] PLATELET/ENDOTHELIUM ATTACHMENT AND SIGNIFICANCE .....	64
<b>SECTION B: ASSESSMENT OF PLATELET AND ENDOTHELIAL FUNCTION .....</b>	<b>65</b>
[B.1] MODELS FOR EVALUATION OF PLATELET FUNCTION .....	65
[B.1.1] <i>Platelet activation/aggregation techniques</i> .....	65
[B.1.1.1] Optical (turbidometric) platelet aggregometry.....	65
[B.1.1.2] Impedance platelet aggregometry .....	65
[B.1.1.3] The rapid platelet function assay (RPFA).....	66
[B.1.1.4] The cone and plate(let) analyzer (CPA).....	66
[B.1.1.5] Other methods .....	67
[B.1.2] <i>Measures of platelet activation</i> .....	67
[B.1.2.1] Activation markers .....	67
[B.2] ASSESSMENT OF ENDOTHELIAL FUNCTION.....	68
[B.2.1] <i>Intra-coronary studies</i> .....	68
[B.2.2] <i>Impedance plethysmography</i> .....	69
[B.2.3] <i>Brachial ultrasound</i> .....	69
[B.2.4] <i>Pulse wave analysis</i> .....	70

<b>SECTION C: DISTURBANCES OF ENDOTHELIAL/PLATELET FUNCTION; RELATIONSHIP TO ISCHAEMIC HEART DISEASE .....</b>	<b>71</b>
[C.1] NORMAL ENDOTHELIAL FUNCTION .....	71
[C.2] ENDOTHELIAL DYSFUNCTION .....	71
[C.2.1] <i>Association with coronary risk</i> .....	72
[C.3] MECHANISM/S OF ENDOTHELIAL DYSFUNCTION .....	72
[C.3.1] <i>Reduced sensitivity to nitric oxide</i> .....	73
[C.3.2] <i>Reduced synthesis of nitric oxide</i> .....	73
[C.3.2.1] <i>Attenuated L-arginine transportation or reduced NOS sub-unit availability</i> .....	73
[C.3.2.2] <i>Inhibition of NOS by asymmetrical dimethyl-L-arginine (ADMA)</i> .....	73
[C.3.2.3] <i>Reduced half life of nitric oxide</i> .....	74
[C.3.2.4] <i>Evidence against reduced synthesis of nitric oxide</i> .....	75
[C.3.3] <i>Angiotensin II</i> .....	76
[C.4] PATHOPHYSIOLOGY OF NAD(P)H OXIDASE .....	76
[C.4.1] <i>Endothelium</i> .....	76
[C.4.2] <i>Genetic polymorphisms</i> .....	76
[C.4.3] <i>Stimuli for NAD(P)H oxidase</i> .....	77
[C.4.3.1] <i>Angiotensin II</i> .....	77
[C.4.3.2] <i>Others</i> .....	78
[C.4.4] <i>Association of NAD(P)H oxidase with endothelial dysfunction</i> .....	78
[C.5] OTHER SOURCES OF REACTIVE OXYGEN SPECIES .....	78
[C.5.1] <i>Xanthine oxidase</i> .....	78
[C.5.2] <i>Endothelial derived nitric oxide synthase</i> .....	79
<b>PHARMACOTHERAPY FOR ENDOTHELIAL DYSFUNCTION .....</b>	<b>80</b>
[C.6.1] <i>Interventions targeting nitric oxide, NOS production/regulation</i> .....	80
[C.6.1.1] <i>L-arginine/tetrahydrobiopterin supplementation</i> .....	80
[C.6.1.2] <i>Cholesterol lowering</i> .....	81
[C.6.2] <i>Interventions that reduce nitric oxide clearance</i> .....	82
[C.6.2.1] <i>Antioxidant pharmacotherapy</i> .....	82
[C.6.2.1.1] <i>Vitamins</i> .....	82
[C.6.2.1.2] <i>Other anti-oxidants</i> .....	83
[C.6.3] <i>Angiotensin-converting enzyme (ACE) inhibition/angiotensin receptor antagonists</i> .....	84
[C.6.4] <i>Summary</i> .....	85
<b>PATHOLOGICAL PLATELET AGGREGATION: .....</b>	<b>86</b>
[C.7] EVIDENCE FOR A ROLE OF PLATELETS IN CARDIOVASCULAR DISEASE STATES .....	86
[C.7.1] <i>Lesion initiation/development</i> .....	86
[C.7.2] <i>Advanced atherosclerotic lesion and plaque rupture</i> .....	86
[C.7.3] <i>Other factors contributing to plaque instability and rupture</i> .....	88
[C.7.4] <i>Implications of plaque rupture</i> .....	89
[C.8] EVIDENCE OF PLATELET HYPER-AGGREGABILITY .....	90
[C.8.1] <i>Stable angina pectoris</i> .....	90
[C.8.2] <i>Unstable angina pectoris and myocardial infarction</i> .....	91
[C.9] EVIDENCE THAT CORONARY ARTERY DISEASE IS ASSOCIATED WITH PLATELET HYPER-AGGREGABILITY .....	92
[C.9.1] <i>Epidemiology</i> .....	92
[C.10] RISK FACTORS FOR ATHEROSCLEROSIS AND PLATELET HYPER-AGGREGABILITY .....	94
[C.10.1] <i>Diabetes</i> .....	94
[C.10.2] <i>Hypercholesterolaemia</i> .....	95
[C.10.2.1] <i>ox-LDL serving as a pro-aggregant</i> .....	95
[C.10.3] <i>Hypertension</i> .....	96
[C.10.4] <i>Smoking</i> .....	97
[C.11] "SICK PLATELET BEHAVIOR" .....	97
[C.12] MECHANISMS .....	97
[C.12.1] <i>Reactive oxygen species serving as pro-aggregants</i> .....	97
[C.12.1.1] <i>Superoxide</i> .....	97
[C.12.1.2] <i>Hydrogen peroxide</i> .....	98
[C.12.1.3] <i>Hydroxyl radical</i> .....	100

[C.12.1.4] Peroxynitrite .....	100
[C.12.2] <i>Products of reactive oxygen species</i> .....	101
[C.12.2.1] Clinical implications .....	101
<b>PHARMACOMODULATION OF PLATELET FUNCTION</b>	
<b>INHIBITION OF PLATELET AGGREGATION: CLINICAL STRATEGIES .....</b>	<b>102</b>
[C.13] ASPIRIN .....	102
[C.13.1] <i>History</i> .....	102
[C.13.2] <i>Prostanoid Structure and Function</i> .....	102
[C.13.3] <i>Mechanism of Action</i> .....	103
[C.13.4] <i>Secondary Prevention of Ischaemic Events</i> .....	104
[C.13.5] <i>Primary Prevention of Ischaemic Events</i> .....	104
[C.14] GLYCOPROTEIN IIb/IIIa RECEPTOR ANTAGONISTS .....	106
[C.14.1] <i>Abciximab (c7E3 Fab)</i> .....	106
[C.14.1.1] Ischaemic heart disease .....	107
[C.14.2] <i>Tirofiban</i> .....	107
[C.14.3] <i>Other GPIIb/IIIa receptor antagonists</i> .....	108
[C.15] ADP RECEPTOR ANTAGONISTS .....	108
[C.15.1] <i>Mechanism of Action</i> .....	109
<b>EFFECTS FROM OTHER CARDIAC DRUGS ON PLATELET FUNCTION .....</b>	<b>110</b>
[C.16] ACE INHIBITORS .....	110
[C.17] STATINS .....	111
[C.18] CALCIUM ANTAGONISTS .....	111
<b>SECTION D: PHARMACOTHERAPY WITH ORGANIC NITRATES AND OTHER</b>	
<b>NITRIC OXIDE DONORS: EFFECTS ON VASOMOTOR AND PLATELET FUNCTION .....</b>	<b>113</b>
[D.1] NITRATE PHARMACOTHERAPY .....	113
[D.1.1] <i>Nitrovasodilators</i> .....	113
[D.1.2] <i>Organic nitrate preparations</i> .....	113
[D.1.2.1] Nitroglycerine (NTG) .....	113
[D.1.2.2] Isosorbide di-nitrate (ISDN) .....	114
[D.1.2.3] Isosorbide mono-nitrate (ISMN) .....	114
[D.1.3] <i>Functional aspects of organic nitrates</i> .....	115
[D.1.3.1] Vasculature .....	115
[D.1.3.2] Platelets .....	116
[D.2] NITRATE TOLERANCE .....	117
[D.2.1] Evidence for tolerance induction: Ischaemic heart disease .....	117
[D.2.2] Congestive Heart Failure .....	118
[D.2.3] Platelets aggregation .....	118
[D.3] PROPOSED MECHANISM/S OF NITRATE TOLERANCE .....	119
[D.3.1] <i>Historical perspective</i> .....	119
[D.3.2] <i>True tolerance</i> .....	120
[D.3.2.1] Impaired nitric oxide release .....	120
[D.3.2.1.1] Attenuated bio-conversion .....	120
[D.3.2.1.2] Bioconversion enzyme .....	120
[D.3.2.1.3] Sulfhydryl hypothesis .....	121
[D.3.2.2] Increased nitric oxide clearance .....	122
[D.3.2.2.1] Evidence against superoxide involvement .....	123
[D.3.2.2.2] Superoxide summary .....	124
[D.3.2.3] Involvement of nitric oxide synthase .....	124
[D.3.3] <i>Pseudotolerance</i> .....	124
[D.3.3.1] Plasma volume expansion .....	125
[D.3.4] <i>Other hypotheses</i> .....	126
[D.4] STRATEGIES THAT MINIMIZE TRUE/PSEUDOTOLERANCE .....	127
[D.4.1] <i>Regimen based</i> .....	127
[D.4.1.1] Low dose and intermittent dosing regimens .....	127
[D.4.2] <i>Co-therapy</i> .....	127
[D.4.2.1] <i>N-acetyl cysteine</i> .....	127

[D.4.2.2] Anti-oxidants .....	128
[D.4.2.3] High dose ACE inhibitors .....	129
[D.4.2.4] Hydralazine .....	130
[D.4.2.5] Other co-therapy .....	130
[D.4.3] <i>Tolerant resistant nitric oxide sources</i> .....	131
[D.4.4] <i>Summary</i> .....	131

**SECTION E: COMBINED DYSFUNCTION OF THE ENDOTHELIUM AND PLATELETS.  
THE CONCEPT OF REDUCED RESPONSIVENESS TO THE ANTI-PLATELET  
AND VASODILATOR PROPERTIES OF NITRIC OXIDE (NITRIC OXIDE RESISTANCE).....131**

[E.1] PHENOMENON .....	131
[E.1.1] <i>Nitric oxide resistance at the vascular level</i> .....	132
[E.1.2] <i>Further evidence of nitric oxide resistance and risk factors for coronary artery disease</i> .....	133
[E.1.3] <i>Nitric oxide resistance and its relationship to endothelial dysfunction</i> .....	134
[E.1.4] <i>Nitric oxide resistance at the platelet level</i> .....	134
[E.2] MECHANISM/S .....	135
[E.2.1] <i>The link generated from diabetes and insulin</i> .....	136
[E.2.2] <i>Reactive oxygen species</i> .....	136

**SECTION F: MAJOR RESIDUAL ISSUES .....137**

**SECTION G: SCOPE OF THE CURRENT STUDY .....138**

**CHAPTER 2: PLATELET HYPER-AGGREGABILITY AND HYPO-RESPONSIVENESS  
TO DONORS OF NITRIC OXIDE; INVOLVEMENT OF THE SUPEROXIDE ANION .....140**

**[2.1] CHAPTER OVERVIEW .....141**

[2.1.1] SUMMARY OF A STUDY EXAMINING THE PHENOMENA OF PLATELET HYPER-AGGREGABILITY AND HYPO-RESPONSIVENESS TO DONORS OF NITRIC OXIDE. ....	141
[2.1.2] SUMMARY OF A STUDY EXAMINING THE DEVELOPMENT OF A DETECTION METHOD FOR SUPEROXIDE IN WHOLE BLOOD SAMPLES. ....	143
[2.1.3] SUMMARY OF A STUDY EXAMINING THE EXTENT OF LDL IN SUBJECTS WITH CORONARY ARTERY DISEASE; RELATIONSHIP TO PLATELET AGGREGABILITY AND HYPO-RESPONSIVENESS TO DONORS OF NITRIC OXIDE .....	144

**[2.2] INTRODUCTION .....145**

[2.2.1] <i>Platelets / activation / aggregation</i> .....	145
[2.2.2] <i>Effects of nitric oxide on platelet aggregation</i> .....	146
Authentic nitric oxide / EDRF .....	146
<i>In vitro</i> .....	146
<i>In vivo/ex vivo</i> .....	146
Mechanism of disparity between <i>in vivo</i> and <i>in vitro</i> effects of nitric oxide.....	148
[2.2.3] <i>Mechanism of inhibition</i> .....	148
Nitric oxide .....	148
[2.2.4] <i>Platelet hyper-aggregability</i> .....	149
Acute coronary syndrome .....	149
Stable angina pectoris .....	149
[2.2.5] <i>Platelet hypo-responsiveness towards nitric oxide / nitro-vasodilators</i> .....	150
[2.2.6] <i>Superoxide: Mechanisms of formation</i> .....	151
[2.2.7] <i>Superoxide: Effects on platelet physiology</i> .....	151
[2.2.8] <i>Detection systems for superoxide</i> .....	152
[2.2.8.1] Cytochrome <i>c</i> reduction .....	152
[2.2.8.2] Electron-spin resonance and spin trapping .....	153
[2.2.8.3] Chemiluminescence reactions .....	154
Lucigenin .....	154
Other compounds .....	155

[2.2.8.4] Protection by superoxide dismutase .....	155
[2.2.8.5] Enhancement of effect by inhibition of superoxide dismutase .....	157
[2.2.8.6] Malondialdehyde and isoprostane ("foot printing") .....	157
Malondialdehyde .....	157
Isoprostanes .....	158
Other lipid peroxidation products .....	158
[2.2.9] Unresolved issues .....	158
<b>[2.3] PLATELET HYPER-AGGREGABILITY AND HYPO-RESPONSIVENESS TO DONORS OF NITRIC OXIDE; THE ROLE OF THE SUPEROXIDE ANION .....</b>	<b>159</b>
[2.3.1] INTRODUCTION.....	159
<i>Platelet hyper-aggregability</i> .....	159
<i>Platelet hypo-responsiveness to nitric oxide</i> .....	160
<i>Role of superoxide</i> .....	161
<i>Experimental study</i> .....	161
[2.3.2] CURRENT STUDY HYPOTHESIS .....	162
[2.3.3] METHODS .....	162
[2.3.3.1] <i>Subjects</i> .....	162
[2.3.3.2] <i>Blood Sampling</i> .....	163
[2.3.3.3] <i>Platelet Aggregation Studies</i> .....	163
[2.3.3.4] <i>Chemicals</i> .....	164
[2.3.3.5] <i>Statistical Analysis</i> .....	164
[2.3.4] RESULTS.....	164
[2.3.4.1] <i>Clinical characteristics</i> .....	164
Medication profile .....	165
[2.3.4.2] <i>Platelet response to ADP</i> .....	166
<i>Platelet aggregability in ACS patients</i> .....	167
[2.3.4.3] <i>Inhibition of Platelet Aggregation by sodium nitroprusside and nitroglycerine</i> .....	168
Platelet responsiveness to SNP .....	169
Platelet responsiveness to NTG .....	170
[2.3.4.4] <i>Mechanism(s) of platelet hypo-responsiveness to donors of nitric oxide</i> .....	171
[2.3.4.5] <i>Mechanism(s) of action</i> .....	172
[2.3.4.5.1] <i>Aggregability</i> .....	172
[2.3.4.5.2] <i>Normal volunteers</i> .....	173
[2.3.4.5.3] <i>Stable angina pectoris patients</i> .....	174
[2.3.4.5.4] <i>Acute coronary syndrome subjects</i> .....	174
[2.3.4.5.5] <i>Inter-relationship between platelet aggregability and the degree of change post administration of SOD/catalase</i> .....	176
[2.3.4.5.6] <i>Platelet responsiveness to SNP</i> .....	177
[2.3.4.5.7] <i>Inter-relationship between SNP responsiveness and the degree of change in SNP responsiveness post SOD/catalase administration</i> .....	178
[2.3.5] DISCUSSION.....	179
<i>Platelet hyper-aggregability</i> .....	180
Phenomenon .....	180
Mechanism/s .....	180
Indirect effects of superoxide causing platelet hyper-aggregability.....	182
<i>Platelet hypo-responsiveness to donors of nitric oxide (nitric oxide resistance)</i> .....	183
Role of superoxide in platelet hypo-responsiveness to donors of nitric oxide .....	183
Alternative mechanism/s.....	184
cGMP-independent effects of nitric oxide .....	185
[2.3.6] STUDY LIMITATIONS .....	186
[2.3.7] CONCLUSIONS .....	187
<b>[2.4] SUPEROXIDE DETECTION IN WHOLE BLOOD.....</b>	<b>188</b>
[2.4.1] INTRODUCTION.....	188
<i>Reactive oxygen species</i> .....	188
<i>Sources of reactive oxygen species in cardiovascular disease states</i> .....	188
<i>Platelets and superoxide</i> .....	189
<i>Detection systems (Lucigenin)</i> .....	189
[2.4.2] CURRENT STUDY HYPOTHESIS .....	191
[2.4.3] METHODS.....	191



[2.4.3.1] Subjects .....	191
[2.4.3.2] Blood Sampling .....	191
[2.4.3.3] Preparation of platelets .....	191
[2.4.3.4] Preparation of neutrophils .....	192
[2.4.3.5] Platelet Aggregation and Chemiluminescence assay for superoxide .....	192
[2.4.3.6] Aggregability and LDCL parameters .....	193
[2.4.3.7] Validation of the LDCL assay .....	193
[2.4.3.8] Chemicals .....	193
[2.4.3.9] Statistical Analysis .....	193
[2.4.4] RESULTS.....	194
[2.4.4.1] Influence of lucigenin on the extent of platelet aggregation .....	194
[2.4.4.2] Superoxide detection in whole blood pre and post platelet aggregation.....	194
[2.4.4.3] Validation of the superoxide detection and release post induction of whole blood platelet aggregation .....	196
[2.4.4.4] Relationship between baseline and aggregation-associated LDCL .....	198
[2.4.4.5] The relationship between the extent of platelet aggregation and the degree of aggregation-associated increase in LDCL.....	199
Aggregability and aggregation-associated LDCL:- ADP (1µM) .....	200
[2.4.4.6] The extent of aggregation-associated LDCL and its relationship to its rate of superoxide generation. ....	201
Aggregation-associated LDCL and rate of generation:- ADP (1µM) .....	202
[2.4.4.7] Platelet aggregation and its relationship to the rate of aggregation-associated LDCL generation. ....	203
Platelet aggregation and rate of aggregation-associated LDCL:- ADP (1µM) .....	204
[2.4.4.8] The rate of platelet aggregation and its relationship to the rate of aggregation-associated LDCL.....	205
Rate of platelet aggregation and rate of aggregation-associated LDCL:- ADP (1µM) .....	206
[2.4.4.9] Lag period .....	207
Lag period and extent of platelet aggregation.....	209
Lag period and extent of aggregation-associated LDCL.....	209
[2.4.4.10] Identification of the source of superoxide .....	210
[2.4.4.11] Further identification of the source of superoxide .....	211
[2.4.4.12] Neutrophil preparations .....	212
[2.4.5] DISCUSSION.....	213
Mechanism of superoxide generation (Baseline and aggregation-associated LDCL) .....	214
Baseline LDCL .....	214
Aggregation-associated LDCL .....	215
Sources / mechanisms .....	216
Platelets as a superoxide source.....	217
[2.4.6] STUDY LIMITATIONS .....	218
[2.4.7] CONCLUSIONS .....	218

<b>[2.5] SUPEROXIDE RELEASE AS MEASURED BY LUCIGENIN - DERIVED CHEMILUMINESCENCE IN SUBJECTS WITH CORONARY ARTERY DISEASE: ITS RELATIONSHIP TO PLATELET HYPER-AGGREGABILITY AND HYPO - RESPONSIVENESS TO NITRIC OXIDE .....</b>	<b>220</b>
[2.5.1] INTRODUCTION.....	220
Modulation of platelet function by reactive oxygen species .....	220
Influence of reactive oxygen species/oxidative stress on responsiveness to nitric oxide.....	220
[2.5.2] CURRENT STUDY HYPOTHESIS .....	221
[2.5.3] METHODS.....	222
[2.5.3.1] Subjects .....	222
[2.5.3.2] Blood Sampling .....	222
[2.5.3.3] Platelet aggregation studies .....	223
[2.5.3.4] LDCL parameters.....	223
[2.5.3.5] Chemicals .....	223
[2.5.3.6] Statistical Analysis .....	223
[2.5.4] RESULTS.....	224
[2.5.4.1] Clinical Characteristics.....	224
Medication profile .....	224



[2.5.4.2] Platelet response to ADP .....	225
[2.5.4.3] Platelet hypo-responsiveness to sodium nitroprusside .....	226
[2.5.4.4] Differences in LDCL across disease states .....	227
Baseline LDCL (lucigenin 125µM) .....	227
Baseline LDCL (lucigenin 12.5µM) .....	228
Aggregation-associated LDCL (lucigenin 125µM) .....	229
Aggregation-associated LDCL (lucigenin 12.5µM) .....	230
[2.5.4.5] The extent of aggregation and its relationship to baseline LDCL .....	231
Lucigenin (125µM) .....	231
Lucigenin (12.5µM) .....	232
[2.5.4.6] The extent of aggregation and its relationship to the aggregation-associated LDCL .....	233
Lucigenin (125µM) .....	233
Lucigenin (12.5µM) .....	234
[2.5.4.7] Platelet responsiveness to SNP and its relationship to baseline LDCL .....	235
Lucigenin (125µM) .....	236
Lucigenin (12.5µM) .....	236
[2.5.4.8] Platelet responsiveness to SNP and its relationship to aggregation-associated LDCL .....	237
Lucigenin (125µM) .....	237
Lucigenin (12.5µM) .....	238
[2.5.5] DISCUSSION .....	239
<i>Lucigenin derived chemiluminescence as a measure of extracellular superoxide; relationship to angina pectoris</i> .....	243
<i>Acute coronary syndromes and inflammation</i> .....	243
<i>Coronary risk factors / disease states and superoxide</i> .....	246
<i>Anti-anginal pharmacotherapies and superoxide</i> .....	247
<i>Platelet aggregability and superoxide</i> .....	248
Baseline LDCL .....	248
Aggregation-associated LDCL .....	249
<i>Platelet responsiveness towards nitric oxide and its relationship to superoxide</i> .....	250
[2.5.6] STUDY LIMITATIONS .....	251
[2.5.7] CONCLUSIONS .....	252
<b>[2.6] CHAPTER SUMMARY .....</b>	<b>253</b>

<b>CHAPTER 3: DETERMINANTS OF PLATELET HYPO-RESPONSIVENESS TO NITRIC OXIDE (NITRIC OXIDE RESISTANCE) .....</b>	<b>255</b>
<b>CHAPTER OVERVIEW .....</b>	<b>256</b>
[3.1] SUMMARY OF THE STUDY EXAMINING THE DETERMINANTS OF PLATELET HYPO-RESPONSIVENESS TO DONORS OF NITRIC OXIDE .....	256
[3.2] INTRODUCTION .....	258
[3.2.1] <i>Endothelial dysfunction/nitric oxide resistance</i> .....	258
[3.2.2] <i>Anti-platelet properties of nitric oxide</i> .....	259
[3.2.3] <i>Platelet hyper-aggregability</i> .....	259
[3.2.4] <i>Significance</i> .....	260
[3.3] STUDY HYPOTHESES .....	260
[3.4] METHODS .....	261
[3.4.1] <i>Subjects</i> .....	261
[3.4.2] <i>Blood Sampling</i> .....	261
[3.4.3] <i>Platelet aggregation studies</i> .....	262
[3.4.4] <i>Chemicals</i> .....	262
[3.4.5] <i>Statistical Analysis</i> .....	262
Categorization of coronary risk factors .....	262
Statistical Analysis .....	262
[3.5] RESULTS .....	263
[3.5.1] <i>Clinical characteristics</i> .....	263
Risk factors .....	263
Medication .....	264
[3.5.2] <i>Platelet aggregability</i> .....	265
Platelet aggregability in ACS patients .....	267

[3.5.3] <i>Inhibition of platelet aggregation by sodium nitroprusside and nitroglycerine</i> .....	269
Platelet responsiveness to sodium nitroprusside.....	269
Platelet responsiveness to nitroglycerine.....	272
<i>Platelet responsiveness to SNP and NTG in ACS patients</i> .....	275
<i>Sodium nitroprusside</i> .....	275
<i>Nitroglycerine</i> .....	276
[3.5.4] <i>Inter-relationship between aggregability and platelet responsiveness to nitric oxide</i> .....	279
Platelet aggregability versus SNP responsiveness.....	279
Platelet Aggregability versus NTG responsiveness.....	281
[3.5.5] <i>Univariate and multivariate analysis</i> .....	284
[3.5.6] <i>Age and platelet responsiveness to SNP and NTG</i> .....	286
Age versus SNP responsiveness.....	286
Age versus nitroglycerine responsiveness.....	288
[3.5.7] <i>Total number of coronary risk factors and platelet responsiveness to SNP and NTG</i> .....	290
Sodium nitroprusside.....	290
Nitroglycerine.....	291
[3.5.8] <i>Extent of coronary artery disease and platelet responsiveness to SNP</i> .....	293
Stable angina pectoris patients.....	293
Acute coronary syndrome subjects.....	293
[3.5.9] <i>Severity of angina and platelet responsiveness to SNP</i> .....	295
[3.6] DISCUSSION.....	296
[3.6.1] <i>Platelet aggregability</i> .....	297
[3.6.2] <i>Platelet responsiveness towards nitric oxide</i> .....	298
[3.6.3] <i>Clinical determinants</i> .....	300
Platelet level.....	300
Vascular level.....	301
Relationship to ischaemic heart disease.....	301
[3.6.4] <i>Pharmacotherapy</i> .....	302
[3.6.4.1] <i>Perhexiline maleate</i> .....	302
Clinical efficacy.....	302
Mechanism of action.....	302
Calcium antagonist.....	302
Carnitine palmitoyltransferase-1 (CPT-1) inhibition.....	303
Effects on myocardium and coronary vasculature.....	303
Anti-platelet properties.....	303
Perhexiline summary.....	304
[3.6.4.2] <i>Statin utilization and hypercholesterolaemia</i> .....	304
Anti-platelet/thrombotic actions of statins.....	305
Plaque stability.....	305
Statin use and endothelial dysfunction.....	306
Reactive oxygen species.....	306
Nitric oxide stimulation.....	306
Reduction of inflammation at the sites of an atherosclerotic lesion.....	307
[3.7] LIMITATION OF THE STUDY.....	307
[3.8] CONCLUSIONS.....	308
[3.9] CHAPTER SUMMARY.....	309

<b>CHAPTER 4: PROPHYLACTIC NITRATE PHARMACOTHERAPY: EVALUATION OF THE ANTI-AGGREGATORY AND ARTERIAL VASOMOTOR EFFECTS</b> .....	<b>311</b>
<b>CHAPTER OVERVIEW</b> .....	<b>312</b>
[4.1] SUMMARY OF THE STUDY EVALUATING THE ANTI-AGGREGATORY AND ARTERIAL VASOMOTOR EFFECTS OF PROPHYLACTIC NITRATE PHARMACOTHERAPY.....	312
[4.2] INTRODUCTION.....	314
[4.2.1] <i>Biological effects of organic nitrates</i> .....	314
Vasodilatation-peripheral and coronary.....	314
Anti-aggregatory.....	315
[4.2.2] <i>Chronic anti-anginal pharmacotherapy with organic nitrates</i> .....	316
Clinical efficacy in stable angina.....	316
Evidence regarding the therapeutic efficacy of ISMN and TD-NTG (intermittent use) as prophylactic.....	316

anti-anginal agents .....	316
ISMN .....	316
TD-NTG .....	317
Evidence for anti-aggregatory effects .....	317
[4.2.3] <i>Pulse wave analysis and the vasomotor effects of organic nitrates</i> .....	318
[4.2.4] <i>“Rebound” and the “zero hour” phenomenon</i> .....	319
[4.2.5] <i>Summary</i> .....	320
[4.3] CURRENT STUDY HYPOTHESIS .....	320
[4.4] METHODS .....	321
[4.4.1] <i>Subjects</i> .....	321
[4.4.2] <i>Patient exclusion criteria</i> .....	321
Clinical parameters .....	321
Experimental parameters .....	322
Criteria for withdrawal from the trial .....	322
[4.4.3] <i>Nitrate pharmacotherapy protocol</i> .....	322
Run-in phase .....	322
Active treatment phases .....	322
Patient assessment periods .....	323
[4.4.4] <i>Blood sampling</i> .....	323
[4.4.5] <i>Investigations</i> .....	323
Aggregability .....	323
Superoxide .....	324
[4.4.6] <i>Haemodynamics</i> .....	324
[4.4.7] <i>Chemicals</i> .....	326
[4.4.8] <i>Statistical Analysis</i> .....	326
[4.5] RESULTS .....	327
[4.5.1] <i>Clinical characteristics</i> .....	327
Medications .....	328
[4.5.2] <i>Adverse effects of the nitrate preparations</i> .....	328
[4.5.2.1] Anginal frequency .....	329
[4.5.3] <i>Platelet and luminescent investigations</i> .....	331
[4.5.3.1] <i>Diurnal variability</i> .....	331
Platelet response to ADP .....	331
Diurnal variability in platelet responsiveness to NTG .....	333
Diurnal variability in platelet responsiveness to SNP .....	334
Diurnal variability in whole blood superoxide .....	335
Pre-aggregation LDCL .....	335
Aggregation-associated LDCL .....	335
[4.5.3.2] <i>Acute nitrate pharmacotherapy</i> .....	335
Anti-aggregatory effects of ISMN and TD-NTG .....	336
ISMN .....	337
TD-NTG .....	337
Changes in platelet responsiveness to nitric oxide donors during acute nitrate pharmacotherapy :- .....	339
Nitroglycerine .....	339
Sodium nitroprusside .....	340
Acute effects of nitrate pharmacotherapy on superoxide production .....	341
Pre-aggregation LDCL .....	341
Aggregation-associated LDCL .....	342
[4.5.3.3] <i>Chronic nitrate pharmacotherapy</i> .....	343
Anti-aggregatory effects .....	343
ISMN .....	343
TD-NTG .....	345
Differences between treatment phases and nitrate preparations .....	346
Aggregability .....	346
Changes in platelet responsiveness to nitric oxide donors during chronic nitrate pharmacotherapy :- .....	347
Nitroglycerine .....	347
Differences between treatment phases and nitrate preparations .....	348
Platelet responsiveness to NTG .....	348
Changes in platelet responsiveness to nitric oxide donors during chronic nitrate pharmacotherapy :- .....	348
Sodium nitroprusside .....	348

Differences between treatment phases and nitrate preparations .....	350
Platelet responsiveness to SNP .....	350
Chronic effects of nitrate pharmacotherapy on superoxide production :- .....	350
Pre-aggregation LDCL .....	350
Aggregation-associated LDCL .....	351
Summary: Luminescence variables .....	352
Differences between treatment phases and nitrate preparations regarding luminescence parameters .....	352
Pre-aggregation LDCL .....	352
Aggregation-associated LDCL .....	352
LDCL data: lucigenin (125 $\mu$ M) .....	352
[4.5.3.4] Potential "rebound" in platelet aggregation .....	353
[4.5.4] Vasomotor investigations .....	356
[4.5.4.1] Systolic blood pressure .....	356
Diurnal variability in systolic blood pressure .....	356
Acute nitrate pharmacotherapy .....	356
Chronic nitrate pharmacotherapy .....	357
Differences between treatment phases and nitrate preparations: systolic blood pressure .....	358
[4.5.4.2] Heart rate .....	359
Diurnal variability .....	359
Acute nitrate pharmacotherapy .....	359
Chronic nitrate pharmacotherapy .....	360
[4.5.4.3] Effects on Augmentation index .....	361
Diurnal variability .....	361
Acute nitrate pharmacotherapy .....	362
Chronic nitrate pharmacotherapy .....	363
"Rebound" in AI(x) .....	365
Differences between the nitrate therapies/treatment phases regarding AI(x) .....	366
[4.5.5] Platelet and luminescence variables in those subjects who had vascular parameters examined .....	367
[4.5.6] AI(x) vs SNP responsiveness .....	368
[4.5.7] Platelet and vascular responsiveness to nitroglycerine .....	369
[4.5.8] Relationship between the percentage fall in AI(x) and platelet responsiveness to NTG .....	370
[4.5.9] Acute platelet NTG responsiveness vs acute platelet superoxide .....	371
Platelet responsiveness to NTG vs pre-aggregation LDCL .....	371
Platelet responsiveness to NTG vs aggregation-associated LDCL .....	371
[4.5.10] Relationship between effects on AI(x) and whole blood superoxide during the acute phase administration of ISMN and TD-NTG .....	373
Pre-aggregation LDCL .....	373
Aggregation-associated LDCL .....	373
[4.6] DISCUSSION .....	375
[4.6.1] Anti-platelet effects of organic nitrates ex vivo .....	375
TD-NTG .....	375
Studies demonstrating significant anti-aggregatory effects .....	375
Studies demonstrating no significant anti-aggregatory effect .....	376
ISMN .....	376
Current study results: lack of significant anti-aggregatory effect .....	377
Clinical .....	377
Experimental .....	378
Summary .....	379
[4.6.2] "Rebound" platelet hyper-aggregability .....	379
[4.6.3] Sensitivity to nitric oxide donors .....	381
Nitrate tolerance .....	381
Platelet vasomotor inter-relationship .....	382
Nitrate tolerance and superoxide .....	382
Nitric oxide resistance .....	384
[4.6.4] Interrelationship between platelet and vascular responsiveness to nitric oxide .....	385
[4.6.5] Superoxide and vascular responsiveness to nitric oxide .....	385
[4.7] LIMITATIONS OF THE STUDY .....	386
[4.8] CONCLUSIONS .....	387
[4.9] CHAPTER SUMMARY .....	387

<b>CHAPTER 5: STUDIES EXAMINING THE PATHOPHYSIOLOGICAL AND ANTI-AGGREGATORY EFFECTS OF NITRIC OXIDE: GENERAL DISCUSSION AND FUTURE DIRECTIONS.....</b>	<b>388</b>
[5.1] INTRODUCTION.....	389
[5.2] STUDIES EXAMINING THE PHENOMENA OF PLATELET HYPER-AGGREGABILITY AND HYPO-RESPONSIVENESS TO DONORS OF NITRIC OXIDE.....	389
[5.2.1] <i>Study purpose and results</i> .....	389
[5.2.2] <i>Implications</i> .....	391
[5.3] STUDIES EXAMINING THE CLINICAL DETERMINANTS OF PLATELET HYPO-RESPONSIVENESS TO NITRIC OXIDE.....	392
[5.3.1] <i>Study purpose and results</i> .....	392
[5.3.2] <i>Implications</i> .....	393
[5.4] STUDIES EVALUATING THE ANTI-AGGREGATORY AND ARTERIAL VASOMOTOR EFFECTS OF PROPHYLACTIC NITRATE PHARMACOTHERAPY.....	393
[5.4.1] <i>Study purpose and results</i> .....	393
[5.4.2] <i>Implications</i> .....	394
[5.5] MAJOR STUDY LIMITATIONS.....	395
[5.6] FUTURE DIRECTIONS/EXPERIMENTS.....	396
[5.6.1] <i>Studies addressing the phenomenon of platelet hyper-aggregability</i> .....	396
[5.6.2] <i>Studies addressing the phenomenon of platelet hypo-responsiveness to donors of nitric oxide</i> ....	397
Delineation of the nexus between hyper-aggregability and hypo-responsiveness to nitric oxide.....	398
Evaluation of the relationship between platelet hypo-responsiveness to nitric oxide and:- .....	399
Therapeutic amelioration of platelet resistance to the anti-aggregatory effects of nitric oxide .....	400
 <b>CHAPTER 6: BIBLIOGRAPHY .....</b>	 <b>401</b>
 <b>CHAPTER 7: APPENDIX.....</b>	 <b>464</b>
DISCUSSION/ANALYSIS OF THE PLATELET/LUMINESCENT VARIABLES OBTAINED FROM THOSE SUBJECTS THAT HAD VASCULAR PARAMETERS EXAMINED.....	482
<i>Platelet aggregability</i> .....	482
<i>Analysis-Acute nitrate effects</i> .....	482
<i>Chronic nitrate effects</i> .....	483
<i>Differences in platelet aggregability between nitrate treatment phases</i> .....	483
<i>Platelet responsiveness to NTG (100µM)</i> .....	484
Acute phase.....	485
Chronic phase.....	485
<i>Differences in platelet responsiveness to NTG (100µM) between the nitrate treatment phases</i> .....	486
<i>Platelet responsiveness to SNP (10µM)</i> .....	487
Acute phase.....	487
Chronic phase.....	487
<i>Differences in platelet responsiveness to SNP (10µM) between nitrate treatment phases</i> .....	488
<i>Acute and chronic effects of nitrate pharmacotherapy on lucigenin derived chemiluminescence</i> .....	489
Pre-aggregation LDCL-Acute phase.....	489
Pre-aggregation LDCL-Chronic phase.....	489
Differences in pre-aggregation LDCL between treatment phases.....	490
Aggregation-associated LDCL-acute phase.....	490
Aggregation-associated LDCL-chronic phase.....	491
Differences in aggregation-associated LDCL between the nitrate treatment phases.....	491
 <b>PUBLICATIONS.....</b>	 <b>493</b>

# Index of Figures

## Chapter 1

Figure 1.1: Assembled phagocyte and non-phagocyte NAD(P)H oxidase enzyme systems .....	43
Figure 1.2: Proposed model of the platelet ADP receptor mediated aggregation .....	50
Figure 1.3: Agonist induced platelet activation .....	55
Figure 1.4: Biochemical mechanism of platelet inhibition by nitric oxide and/or endothelial derived relaxing factor.....	61
Figure 1.5: Endothelial dysfunction: Mechanisms and pharmacotherapeutic interventions .....	85
Figure 1.6: Plaque erosion/rupture leading to thrombus formation .....	89
Figure 1.7: Prostanoid biosynthesis .....	103
Figure 1.8: Chemical structures of the nitroglycerine (Glyceryl tri-nitrate) and isosorbide dinitrate along with their respective metabolites .....	115

## Chapter 2

Figure 2.3.1: Platelet aggregability and responsiveness to donors of nitric oxide .....	168
Figure 2.3.2: Platelet responsiveness to SNP .....	170
Figure 2.3.3: Platelet responsiveness to NTG .....	171
Figure 2.3.4: Effect of SOD/catalase on extent of ADP-induced platelet aggregation .....	172
Figure 2.3.5: Effects of SOD/catalase on extent of ADP-induced platelet aggregation .....	175
Figure 2.3.6: The extent of ADP-induced platelet aggregation correlated change in platelet aggregation post addition of SOD/catalase .....	176
Figure 2.3.7: Effects of SOD/catalase on platelet responsiveness to SNP .....	177
Figure 2.3.8: Platelet responsiveness to SNP correlated with change post SOD/catalase administration .....	179
Figure 2.4.1: Superoxide detection in whole blood pre and post platelet aggregation .....	195
Figure 2.4.2: Inhibition of baseline and aggregation-associated superoxide generation by SOD .....	197
Figure 2.4.3: Relationship between the extent of baseline and aggregation-associated LDCL .....	198
Figure 2.4.4: Platelet aggregability and aggregation-associated increase in LDCL .....	200
Figure 2.4.5: The extent of platelet aggregation and the degree of aggregation-associated LDCL .....	201
Figure 2.4.6: Aggregation-associated LDCL and its relationship to rate of generation .....	203
Figure 2.4.7: Platelet aggregability and the rate of aggregation-associated LDCL generation .....	205
Figure 2.4.8: Rate of platelet aggregability and the rate of aggregation-associated LDCL .....	207
Figure 2.4.9: Concentration of ADP and the lag period .....	208
Figure 2.4.10: Lag period as a function of platelet aggregation and aggregation-associated LDCL .....	210
Figure 2.4.11: Luminescence and aggregation curves for PRP/PRP and washed platelet preparations .....	211
Figure 2.4.12: Luminescence and aggregation curves from a series of platelet preparations .....	212
Figure 2.4.13: Luminescence curve generated from neutrophil preparations .....	213
Figure 2.5.1: Platelet hypo-responsiveness to SNP .....	226
Figure 2.5.2: Baseline LDCL .....	229
Figure 2.5.3: Aggregation-associated LDCL .....	231
Figure 2.5.4: Platelet aggregability and baseline LDCL .....	233
Figure 2.5.5: Platelet aggregability and aggregation-associated LDCL .....	235
Figure 2.5.6: Platelet responsiveness to SNP and baseline LDCL .....	237
Figure 2.5.7: Platelet responsiveness to SNP and aggregation-associated LDCL .....	239
Figure 2.5.8: Platelet aggregability and LDCL (SAP and ACS patients) .....	240
Figure 2.5.9: Platelet responsiveness to SNP and LDCL (SAP and ACS patients) .....	242

### Chapter 3

Figure 3.1: Differential inhibition of platelet aggregation by aspirin.....	267
Figure 3.2: Inhibition of platelet aggregation by SNP .....	272
Figure 3.3: Inhibition of platelet aggregation by NTG .....	275
Figure 3.4: Platelet responsiveness to SNP and NTG in ACS patients .....	278
Figure 3.5: Aggregability versus SNP responsiveness .....	281
Figure 3.6: Aggregability versus NTG responsiveness .....	283
Figure 3.7: Univariate analysis of coronary risk factors and pharmacotherapy with responsiveness to SNP ...	285
Figure 3.8: Age versus platelet responsiveness to SNP .....	287
Figure 3.9: Age versus platelet responsiveness to NTG .....	289
Figure 3.10: Coronary risk factors as a determinant of platelet responsiveness to SNP .....	291
Figure 3.11: Coronary risk factors as a determinant of platelet responsiveness to NTG .....	292
Figure 3.12: Extent of coronary artery disease and platelet responsiveness to SNP .....	295
Figure 3.13: Angina severity and platelet responsiveness to SNP .....	296

### Chapter 4

Figure 4.1: A representative sphygmocardiogram .....	325
Figure 4.2: Schematic representation of the nitrate treatment regimen .....	327
Figure 4.3: Angina pectoris episodes and additional nitrate consumption during trial .....	330
Figure 4.4: Diurnal variability in platelet response to ADP .....	332
Figure 4.5: Diurnal variability in platelet responsiveness to NTG .....	333
Figure 4.6: Diurnal variability in platelet responsiveness to SNP .....	334
Figure 4.7: Diurnal variability in whole blood superoxide.....	336
Figure 4.8: Acute effects of ISMN and TD-NTG on ADP-induced aggregation .....	338
Figure 4.9: Influence of acute nitrate administration on platelet responsiveness to NTG .....	340
Figure 4.10: Influence of acute nitrate administration on platelet responsiveness to SNP .....	341
Figure 4.11: Acute administration of nitrates and its effects on whole blood superoxide generation .....	343
Figure 4.12: Chronic effects of ISMN pharmacotherapy on ADP-induced aggregation .....	344
Figure 4.13: Chronic effects of TD-NTG pharmacotherapy on ADP-induced aggregation .....	345
Figure 4.14: Effects of chronic nitrate pharmacotherapy on platelet responsiveness to NTG .....	348
Figure 4.15: Chronic nitrate pharmacotherapy: effects on platelet responsiveness to SNP.....	349
Figure 4.16: Chronic nitrate administration:- effects on whole blood superoxide .....	351
Figure 4.17: "Rebound" in platelet aggregability .....	355
Figure 4.18: Acute effects of nitrate pharmacotherapy on systolic blood pressure .....	357
Figure 4.19: Chronic effects of nitrate pharmacotherapy on systolic blood pressure .....	358
Figure 4.20: Acute effects of nitrate pharmacotherapy on heart rate .....	360
Figure 4.21: Chronic effects of nitrate pharmacotherapy on heart rate .....	361
Figure 4.22: Diurnal variability in AI(x) .....	362
Figure 4.23: Acute nitrate effects on AI(x) .....	363
Figure 4.24: Chronic nitrate pharmacotherapy and its effects on AI(x) .....	364
Figure 4.25: "Rebound" in AI(x).....	365
Figure 4.26: Differences between therapies and treatment phases .....	367
Figure 4.27: AI(x) versus platelet responsiveness to SNP .....	368
Figure 4.28: Acute platelet responsiveness to NTG versus AI(x) .....	369
Figure 4.29: Relationship between absolute reduction in AI(x) at 4hrs and the degree of platelet responsiveness to NTG.....	370
Figure 4.30: Relationship between acute platelet responsiveness to NTG and the degree of whole blood superoxide levels.....	372
Figure 4.31: Relationship between delta AI(x) and the degree of whole blood superoxide .....	374

### Chapter 7

Appendix Figure 1: Acute/chronic anti-aggregatory effects of ISMN and TD-NTG .....	484
Appendix Figure 2: Influence of acute/chronic nitrate administration on the degree of platelet responsiveness to NTG.....	486
Appendix Figure 3: Influence of acute/chronic nitrate administration on the degree of platelet responsiveness to SNP .....	488
Appendix Figure 4: Influence of acute/chronic nitrate administration on the degree of LDCL .....	492



# List of Tables

## Chapter 1

Table 1.1: <i>Abbreviations used in this chapter</i> .....	32
Table 1.2: <i>Nitrovasodilators</i> .....	113

## Chapter 2

Table 2.1: <i>Abbreviations used in this chapter</i> .....	145
Table 2.2: <i>Clinical characteristics of the SAP and ACS patients</i> .....	165
Table 2.3: <i>Platelet aggregability in response to ADP</i> .....	166
Table 2.4: <i>Platelet aggregability across subject populations, genders and aspirin pharmacotherapy, three-way ANOVA contingency table</i> .....	167
Table 2.5: <i>Platelet aggregability in response to ADP in UAP and NQAMI patients</i> .....	168
Table 2.6: <i>Three-way repeated measures ANOVA contingency table</i> .....	173
Table 2.7: <i>Clinical characteristics of the SAP and ACS patients</i> .....	225
Table 2.8: <i>Platelet aggregation in response to ADP</i> .....	226

## Chapter 3

Table 3.1: <i>Abbreviations used in this chapter</i> .....	257
Table 3.2: <i>Clinical characteristics of the patient cohorts</i> .....	264
Table 3.3: <i>Platelet aggregability in response to ADP</i> .....	265
Table 3.4: <i>Platelet response to ADP, Two-way ANOVA contingency table</i> .....	266
Table 3.5: <i>Platelet response to ADP, Three-way ANOVA contingency table</i> .....	266
Table 3.6: <i>Platelet aggregability in response to ADP (ACS patients)</i> .....	268
Table 3.7: <i>Platelet response to ADP (ACS patients), three-way ANOVA contingency table</i> .....	269
Table 3.8: <i>Platelet responsiveness to SNP, Two-way ANOVA contingency table</i> .....	270
Table 3.9: <i>Platelet responsiveness to SNP, Three-way ANOVA contingency table</i> .....	271
Table 3.10: <i>Platelet responsiveness to NTG, Two-way ANOVA contingency table</i> .....	273
Table 3.11: <i>Platelet responsiveness to NTG, Three-way ANOVA contingency table</i> .....	274
Table 3.12: <i>Platelet responsiveness to SNP (ACS patients), three-way ANOVA contingency table</i> .....	276
Table 3.13: <i>Platelet responsiveness to NTG (ACS patients), three-way ANOVA contingency table</i> .....	277
Table 3.14: <i>Platelet aggregability versus SNP responsiveness, regression and ANCOVA summary table</i> .....	280
Table 3.15: <i>Platelet aggregability versus NTG responsiveness, regression and ANCOVA summary table</i> .....	282
Table 3.16: <i>Multivariate analysis of patient characteristics</i> .....	285
Table 3.17: <i>Age versus SNP responsiveness, regression and ANCOVA summary table</i> .....	287
Table 3.18: <i>Age versus NTG responsiveness, regression and ANCOVA summary table</i> .....	289
Table 3.19: <i>Coronary risk factors influencing platelet responsiveness to SNP, three-way ANOVA contingency table</i> .....	290
Table 3.20: <i>Coronary risk factors influencing platelet responsiveness to NTG, three-way ANOVA contingency table</i> .....	292
Table 3.21: <i>Numbers of vessels with a major stenosis and its relationship to SNP responsiveness in ACS patients, two-way ANOVA contingency table</i> .....	294

## Chapter 4

Table 4.1: <i>Abbreviations used in this chapter</i> .....	314
Table 4.2: <i>Clinical determinants of the study cohort</i> .....	328
Table 4.3: <i>Medication profile of the study cohort</i> .....	328
Table 4.4: <i>Anti-aggregatory effect of acute nitrate pharmacotherapy:- three-way ANOVA contingency table</i> .....	339
Table 4.5: <i>Effect of chronic nitrate pharmacotherapy of ADP responses:- three-way ANOVA contingency table</i> .....	346

Table 4.6: Differences across phases and between nitrate treatments (platelet response to ADP):- three-way ANOVA contingency table .....	347
Table 4.7: Differences in LDCL at the zero-hr time point for two concentrations of lucigenin .....	353
Table 4.8: Differences across phases and between nitrate treatments (systolic blood pressure), three-way ANOVA contingency table .....	359
Table 4.9: Three-way ANOVA contingency table .....	366

## Chapter 7

Appendix Table 1: Patient number differences for coronary risk factors and anti-anginal pharmacotherapy (Comparison of SAP and ACS patients) .....	465
Appendix Table 2: Platelet responsiveness to SNP and its relationship to disease state, gender and aspirin pharmacotherapy (Gaussian distribution) .....	465
Appendix Table 3: Platelet responsiveness to SNP, 3-way ANOVA contingency table .....	466
Appendix Table 4: Patient number differences for coronary risk factors and anti-anginal pharmacotherapy (SAP and ACS patients) .....	466
Appendix Table 5: Patient number differences for coronary risk factors and pharmacotherapy (Comparison of SAP and ACS patients) .....	467
Appendix Table 6: Patient number differences for coronary risk factors and anti-anginal pharmacotherapy (Comparison of SAP and ACS patients with NIPs) .....	468
Appendix Table 7: Platelet response to ADP (Gaussian distribution) .....	469
Appendix Table 8: Significant results from Bonferroni's post hoc multiple comparison test .....	469
Appendix Table 9: Significant results from Bonferroni's post hoc multiple comparison test .....	470
Appendix Table 10: Platelet responsiveness to SNP, relationship to disease state, gender and aspirin pharmacotherapy (Gaussian distribution) .....	470
Appendix Table 11: Platelet responsiveness to SNP, relationship to disease state, gender and aspirin pharmacotherapy (Gaussian distribution) .....	471
Appendix Table 12: Platelet responsiveness to SNP, relationship to disease state, gender and aspirin pharmacotherapy (Gaussian distribution) ACS patients .....	471
Appendix Table 13: Platelet responsiveness to NTG, relationship to disease state, gender and aspirin pharmacotherapy (Gaussian distribution) ACS patients .....	472
Appendix Table 14: Platelet response to ADP versus platelet responsiveness to SNP .....	472
Appendix Table 15: Platelet response to ADP versus platelet responsiveness to NTG .....	473
Appendix Table 16: Age versus platelet responsiveness to SNP .....	473
Appendix Table 17: Age versus platelet responsiveness to NTG .....	474
Appendix Table 18: Platelet responsiveness to SNP as a function of the number of coronary risk factors .....	474
Appendix Table 19: Platelet responsiveness to NTG as a function of the number of coronary risk factors .....	475
Appendix Table 20: Diurnal variability in platelet response to ADP .....	475
Appendix Table 21: Acute nitrate effects on platelet response to ADP .....	476
Appendix Table 22: Chronic nitrate effects on platelet response to ADP .....	477
Appendix Table 23: Differences between treatment phases and nitrate preparations (platelet responsiveness to ADP) .....	478
Appendix Table 24: Differences between treatment phases and nitrate preparations (platelet responsiveness to NTG) .....	478
Appendix Table 25: Differences between treatment phases and nitrate preparations (platelet responsiveness to SNP) .....	479
Appendix Table 26: Differences between treatment phases and nitrate preparations (pre-aggregation LDCL) .....	479
Appendix Table 27: Pre-aggregation LDCL: three-way ANOVA contingency table .....	480
Appendix Table 28: Differences between treatment phases and nitrate preparations (Aggregation- associated LDCL) .....	480
Appendix Table 29: Aggregation-associated LDCL, three-way ANOVA contingency table .....	481
Appendix Table 30: Differences between treatment phases and nitrate preparations (Systolic blood pressure) .....	481

---

---

# Thesis Summary

---

---

## *Background*

The phenomenon of platelet hyper-aggregability, documented in several cardiovascular disease states, is a factor that predisposes subjects towards pathological thrombotic events. Moreover, decreased platelet responsiveness to exogenously donated nitric oxide, implying reduced sensitivity to both nitric oxide donors and to endogenous sources of nitric oxide, with the resultant failure to regulate platelet function, may also contribute to the pathological complications associated with coronary artery disease (CAD).

The series of studies described herein were designed to firstly examine the phenomenon of platelet hyper-aggregability and attenuated platelet responsiveness to donors of nitric oxide in a series of patient cohorts. The first series of experiments was also designed to examine what role superoxide plays within each phenomenon. In doing so a whole blood superoxide detection method was established. Following on from these initial investigations, a study was then undertaken to examine potential determinants of reduced platelet responsiveness to nitric oxide. Finally, the thesis examined the anti-aggregatory and vasomotor effects of acute and chronic nitrate pharmacotherapy in a cohort of subjects with mild to moderate stable angina pectoris (SAP). As the final investigation was performed in a randomized fashion, an examination of the effects of nitrate pharmacotherapy on the phenomenon of reduced platelet responsiveness to nitric oxide was performed, along with an examination of the phenomenon of nitrate tolerance development following chronic nitrate exposure. An examination of the incidence of possible platelet hyper-aggregability upon acute nitrate withdrawal, as a means of explaining the phenomenon of “rebound” ischaemia, was also performed.

---

---